ALK-positive lung cancer: choosing treatment and planning for resistance

Confirm what ALK positive means

ALK testing looks for an abnormal rearrangement that drives cancer growth. Laboratories can use protein staining, fluorescence testing or sequencing, with further testing when results need clarification. The finding should be interpreted together with the pathology diagnosis.

Ask for the original result and the method used. If two reports disagree, the practical question is whether another assay or pathology review will settle treatment eligibility. Most treatment discussions concern NSCLC, so a change in the underlying diagnosis also needs attention.

Sources and references: [1] [2]

Compare the first ALK inhibitor as a long-term choice

Alectinib, brigatinib and lorlatinib are examples of ALK inhibitors used for advanced ALK-positive NSCLC in appropriate settings. Their evidence, brain activity and adverse-effect profiles differ. The choice should take account of the whole clinical picture rather than selecting by a generation number alone.

Ask how the proposed medicine compares with the main alternative for someone with your health conditions. Discuss how frequently scans and laboratory tests will be needed, what follow-up can happen locally and how a side effect would be managed before treatment is abandoned.

Sources and references: [1]

Brain assessment belongs in the plan

ALK-positive cancer can involve the central nervous system, and several ALK inhibitors have meaningful intracranial activity. Brain MRI helps establish the starting point and provides a comparison for later scans. A normal neurological examination does not answer every imaging question.

When brain metastases are present, medical and radiation specialists weigh systemic treatment against local treatment or a combination. Symptoms, lesion size and risk to nearby structures affect timing. New seizures, weakness or confusion require urgent care, even if a targeted medicine has previously controlled the cancer well.

Sources and references: [1]

Choose around the side effects that matter to you

ALK inhibitors have different monitoring requirements. Some can affect liver tests, heart rate, muscle enzymes or lung health. Lorlatinib commonly requires attention to blood lipids and can cause cognitive or mood effects. Tell the team about existing mental-health concerns and your work or driving responsibilities.

Keep a record of changes that appear after treatment begins. A clinician-directed interruption or adjustment may allow treatment to continue. Avoid independently reducing tablets or using supplements for side effects, as these changes can alter drug exposure or complicate assessment.

Sources and references: [1] [3]

One growing site may lead to a different decision

If most disease remains controlled and only a small number of sites grow, the team may consider local treatment to those sites while reassessing the systemic plan. Whether this is appropriate depends on the location, pace and extent of progression.

Ask the oncologist to compare current scans with the best response, not only the immediately previous study. If the brain is the only changing site, the options may differ from widespread progression in several organs. The aim is to understand what is escaping control before choosing the next step.

Sources and references: [1]

Retesting can help explain resistance

A blood-based test or tissue biopsy can sometimes identify an ALK resistance alteration or another mechanism. The relevance of the result depends on which inhibitors were used before. Tissue can also help when a change in cancer type is suspected.

Ask what the test could change: selection of another ALK inhibitor, entry into a trial or a move to chemotherapy. A negative blood test may need further evaluation. Avoid interpreting a laboratory list as a treatment sequence without considering the clinical history.

Sources and references: [2] [3]

Chemotherapy and trials remain part of the pathway

After targeted treatment, chemotherapy may provide another option when an effective ALK-directed route is unavailable or unsuitable. Clinical trials may study new inhibitors or resistance strategies. Eligibility often depends on the precise prior-drug sequence and current test results.

Start trial discussions before an urgent switch becomes necessary when possible. Ask about washout periods, required biopsies and monitoring. The existing team should help judge whether the cancer can safely wait for screening or whether another treatment needs to begin sooner.

Sources and references: [1] [4]

Bring the treatment sequence to a Shanghai review

For ALK-positive disease, the names, dates and reasons for stopping previous medicines are especially useful. EastMedGo can help organize an appointment inquiry around an initial choice, difficult side effects or resistance. Relevant background is available through the lung cancer page.

Include brain imaging and the full ALK report, along with recent scans. We can help clarify what the receiving hospital needs to assess the question and what coordination arrangements are involved. If a new biopsy or trial is proposed, ask the hospital to explain its purpose before travel is finalized.

Common questions